Proposed rule would streamline registration for advanced distributed manufacturers and increase visibility into foreign drug supply sourcesSilver Spring, MD, July 10, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a proposed rule that, if finalized, would create a streamlined registration pathway for distributed manufacturing establishments that operate as a single establishment using a “hub-and-spoke” model. The proposed rule would also clarify registration requir

New commentary argues that the next breakthrough in medicine may come not only from discovering new therapies, but from redesigning the systems that bring them to patients NASHVILLE, Tenn., July 10, 2026 /PRNewswire/ -- A newly published commentary by TAM Global founder Edward Clay and Annette Marleau, Ph.D., proposes a first-principles framework for accelerating translational medicine and reducing the time it takes for scientific discoveries to reach patients. Published July 3, 2026, in Transla

The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and rivoceranib at the FDA. U.S. regulators have declined to approve the anti-PD-1/VEGFR combo for a third time as a first-line treatment for liver cancer, Hengrui and Elevar’s parent company, HLB Group, said in separate announcements Friday. The problem, again, is manufacturing. Only this time, the complete response letter (CRL) stemmed from deficiencies the FDA had identified in

Longevity Medical Institute® Publishes Peer-Reviewed Meta-Analysis Demonstrating Durable Benefits of Umbilical Cord Stem Cells for Knee Osteoarthritis. One of the most important questions patients ask is not simply whether a treatment works, but how long the improvement will last.” — Dr Kirk Sanford SAN JOSé DEL CABO, BAJA CALIFORNIA SUR, MEXICO, July 10, 2026 / EINPresswire.com / -- Physicians and scientists from Longevity Medical Institute ® have published a new peer-reviewed systematic review

DELRAY BEACH, Fla., July 10, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Point of Care Diagnostics Market is projected to grow from about USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at a CAGR of 8.8%. Browse 250 market data Tables and 100 Figures spread through 300 Pages and in-depth TOC on 'Point of Care Diagnostics Market - Global Forecast to 2031' Point of Care Diagnostics Market Size & Forecast: Market Size Available for Years: 2025–2031 2026 Market Size: USD 20.63

Profound Treatment provides 24/7 medically supervised residential detox, empowering Los Angeles residents to reclaim their lives from opioid addiction. LOS ANGELES, CA, UNITED STATES, July 10, 2026 / EINPresswire.com / -- Profound Treatment continues their awareness-focused initiative to address the opioid crisis in Los Angeles, elevating access to medically supervised residential detox and comprehensive opioid addiction care. As overdose deaths linked to synthetic opioids surge, Profound presen

Global investment giant KKR has launched Allyntra as a new, precision-engineered solutions platform for the medtech industry while also announcing several senior management changes. The Allyntra debut is part of the investment firm’s strategy to support the medtech arena with design, prototyping, and micro-manufacturing of highly specialized components, surgical tools, and diagnostic systems that demand microscopic tolerances. Precipart, a CDMO that specializes in precision components for both t

Nearly half of US adults have high blood pressure, yet only about 1 in 4 has it under control, and the latest federal data suggest the gap is widening. MIAMI, FL, UNITED STATES, July 10, 2026 / EINPresswire.com / -- High blood pressure is often called the silent killer because it usually carries no symptoms, which is part of why so many cases go unmanaged. The federal figures describe a problem measured in tens of millions of people: about 48 percent of adults, roughly 120 million, have high blo

MIAMI, July 10, 2026 /PRNewswire/ -- OpenEvidence, America's most widely used medical knowledge platform, today announced EvidenceGrade, a new feature that grades and visualizes, in real time, the quality of the published evidence cited in—and used to inform—every answer. Continue Reading OpenEvidence Launches EvidenceGrade™, Empowering Physicians To See the Strength of Cited Evidence Beneath Each AI Answer OpenEvidence Launches EvidenceGrade™, Empowering Physicians To See the Strength of Cited

Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking